Vasopressin V2 receptor signaling has also been shown to be a potent inducer of cAMP, and in 2015, Tolvaptan, a highly selective vasopressin V2 receptor antagonist, was approved to slow the progression of cyst development and eGFR decline in patients with ADPKD [7] but due to a relatively unfavorable side effect/benefit ratio it has been suggested to limit therapy with tolvaptan to patients at risk of rapidly progressing ADPKD [8]. The gene discussed is AVPR2; the disease is autosomal dominant polycystic kidney disease.